Itoh Kuniaki | Division Of Hematology Department Of Internal Medicine Hyogo College Of Medicine

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
Phase I Study of Intravenous PSC-833 and Doxorubicin: Reversal of Multidrug Resistance
Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Phase III Study of Ranimustine, Cyclophosphamide, Vincristine, Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple Myeloma : A Japan Clinical Oncology Group Study, JCOG 9301
Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice
Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients
Extragonadal germ cell tumors in Japan
Treatable Subsets in Cancer of Unknown Primary Origin
Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Recurrent Breast Cancer Treated Successfully with Mitomycin-C and Vinblastine after Failure of Both Doxorubicin-containing Regimen and Paclitaxel : A Case Report
A Limited Sampling Model for Estimating Pharmacokinetics of CPT-11 and Its Metabolite SN-38
Pharmacological Correlation between Total Drug Concentration and Lactones of CPT-11 and SN-38 in Patients Treated with CPT-11
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Review of primary unknown cancer : cases referred to the National Cancer Center Hospital East
Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low-and low-intermediate risk, aggressive non-Hodgkin's lymphoma : final results of the Japan Clinical Oncology Group Study, JCOG95

もっと見る

スポンサーリンク